Home	Fast Track My Amedeo FAQ About	Flying Publisher
Fast Track	FPG #8: Alternative Treatments in Psychiatry FPG #7: Critical Care in Neurology	Free Medical Books

Drug Resistance

Free Subscription Articles published in AIDS Retrieve available abstracts of 67 articles: HTML format Text format

Single Articles

October 2011
1. GIBSON JN , Fulco PP
   Concurrent atazanavir and voriconazole in a patient with multidrug-resistant HIV and a mycetoma.
   AIDS. 2011;25:2054-6.
   PubMed     Text format     Related articles   
   
   
   
   
2. SMITH RA , Raugi DN, Kiviat NB, Hawes SE, et al
   Phenotypic Susceptibility of HIV-2 to Raltegravir: Integrase Mutations Q148R and N155H Confer Raltegravir Resistance.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   August 2011
3. GAZZARD B , Duvivier C, Zagler C, Castagna A, et al
   Phase 2 double-blind, randomised trial of etravirine versus efavirenz in treatment-naive patients: 48 week results.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
4. SORIANO V , Sherman KE, Rockstroh J, Dieterich D, et al
   Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
5. AGHOKENG AF , Kouanfack C, Laurent C, Ebong E, et al
   Scale-up of antiretroviral treatment in Cameroon is accompanied by increasing HIV-1 drug resistance mutations in drug-naive patients.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
6. MUKHERJEE R , Jensen ST, Male F, Bittinger K, et al
   Switching between raltegravir resistance pathways analyzed by deep sequencing.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   June 2011
7. LLIBRE JM , Arribas JR, Domingo P, Gatell JM, et al
   Clinical implications of fixed-dose coformulations of antiretrovirals on the outcome of HIV-1 therapy.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   May 2011
8. HUNT GM , Coovadia A, Abrams EJ, Sherman G, et al
   HIV-1 drug resistance at antiretroviral treatment initiation in children previously exposed to single-dose nevirapine.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
9. SCHADER SM , Colby-Germinario SP, Schachter JR, Xu H, et al
   Synergy against drug resistant HIV-1 with the microbicide antiretrovirals, dapivirine and tenofovir, in combination.
   AIDS. 2011.
   PubMed     Text format     Related articles    Abstract available
   
   
   
   
10. GONZALEZ E , Ballana E, Clotet B, Este JA, et al
    Development of Resistance to VIR-353 with cross-resistance to the natural HIV-1 Entry Virus Inhibitory Peptide (VIRIP).
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2011
11. PAINTSIL E
    Resistance, resistance, go away: persistence of nevirapine-resistant HIV mutations in HIV-infected infants.
    AIDS. 2011;25:997-9.
    PubMed     Text format     Related articles   
    
    
    
    
12. FOGEL J , Hoover DR, Sun J, Mofenson LM, et al
    Analysis of nevirapine resistance in HIV-infected infants who received extended nevirapine or nevirapine/zidovudine prophylaxis.
    AIDS. 2011;25:911-917.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
13. NEOGI U , Shet A, Shamsundar R, Ekstrand ML, et al
    Selection of NNRTI-associated mutations in HIV-1 subtype C in India: evidence of etravirine cross-resistance.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
14. LATINOVIC O , Le N, Reitz M, Pal R, et al
    Synergistic inhibition of R5 HIV-1 by maraviroc and CCR5 antibody HGS004 in primary cells: implications for treatment and prevention.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
15. METIFIOT M , Vandegraaff N, Maddali K, Naumova A, et al
    Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2011
16. NDEMBI N , Hamers RL, Sigaloff KC, Lyagoba F, et al
    Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala, Uganda.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2011
17. CAHN P , Fourie J, Grinsztejn B, Hodder S, et al
    ODIN: 48-week analysis of once- versus twice-daily darunavir/ritonavir in treatment-experienced HIV-1-infected patients.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
18. HIDRON AI , Moanna A, Rimland D
    The rise and fall of MRSA infections in HIV patients.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
19. GALLIEN S , Delaugerre C, Charreau I, Braun J, et al
    Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
20. BANSI L , Smith C, Phillips A, Kirk S, et al
    The impact of HIV drug resistance testing on changes to treatment.
    AIDS. 2011.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2011
21. PARIENTI JJ
    Darunavir/ritonavir monotherapy in clinical practice.
    AIDS. 2011;25:119.
    PubMed     Text format     Related articles   
    
    
    
    December 2010
22. GOODMAN DD , Zhou Y, Margot NA, McColl DJ, et al
    Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
23. ORMSBY CE , Rosa-Zamboni DD, Vazquez-Perez J, Ablanedo-Terrazas Y, et al
    Severe 2009 pandemic influenza A (H1N1) infection and increased mortality in patients with late and advanced HIV disease.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2010
24. MARTIN-CARBONERO L , Teixeira T, Poveda E, Plaza Z, et al
    Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2010
25. BANGSBERG DR , Ragland K, Monk A, Deeks SG, et al
    A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV+ homeless and marginally housed people.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2010
26. CHARPENTIER C , Larrouy L, Collin G, Damond F, et al
    In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2010
27. KATLAMA C , Valantin MA, Algarte-Genin M, Duvivier C, et al
    Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
28. CHARPENTIER C , Roquebert B, Colin C, Taburet AM, et al
    Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
29. TAYLOR S , Jayasuriya AN, Berry A, Gilleran G, et al
    Darunavir concentrations exceed the protein-corrected EC50 for wild-type HIV in the semen of HIV-1-infected men.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
30. FOURATI S , Malet I, Binka M, Boukobza S, et al
    Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    July 2010
31. COHEN AL , Harrison LH, Farley MM, Reingold AL, et al
    Prevention of invasive pneumococcal disease among HIV-infected adults in the era of childhood pneumococcal immunization.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
32. BAR-MAGEN T , Donahue DA, McDonough EI, Kuhl BD, et al
    HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
33. GUPTA RK , Kohli A, McCormick AL, Towers GJ, et al
    Full-length HIV-1 Gag determines protease inhibitor.
    AIDS. 2010;24:1651-5.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
34. HAMKAR R , Mohraz M, Lorestani S, Aghakhani A, et al
    Assessing subtype and drug-resistance-associated mutations among antiretroviral-treated HIV-infected patients.
    AIDS. 2010;24 Suppl 2:S85-91.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2010
35. HARRISON L , Castro H, Cane P, Pillay D, et al
    The effect of transmitted HIV-1 drug resistance on pre-therapy viral load.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
36. DELOBEL P , Raymond S, Mavigner M, Cazabat M, et al
    Shift in phenotypic susceptibility suggests a competition mechanism in a case of acquired resistance to maraviroc.
    AIDS. 2010;24:1382-4.
    PubMed     Text format     Related articles   
    
    
    
    May 2010
37. EL-KHATIB Z , Ekstrom AM, Ledwaba J, Mohapi L, et al
    Viremia and drug resistance among HIV-1 patients on antiretroviral treatment: a cross-sectional study in Soweto, South Africa.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    April 2010
38. MURPHY RA , Sunpath H, Lu Z, Chelin N, et al
    Outcomes after virologic failure of first-line ART in South Africa.
    AIDS. 2010;24:1007-12.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
39. WHEELER WH , Ziebell RA, Zabina H, Pieniazek D, et al
    Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
40. KELLEY CF , Sullivan ST, Lennox JL, Evans-Strickfaden T, et al
    Lack of effect of compartmentalized drug resistance mutations on HIV-1 pol divergence in antiretroviral-experienced women.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    March 2010
41. VAN HALSEMA CL , Fielding KL, Chihota VN, Russell EC, et al
    Tuberculosis outcomes and drug susceptibility in individuals exposed to isoniazid preventive therapy in a high HIV prevalence setting.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
42. DORE GJ , Soriano V, Rockstroh J, Kupfer B, et al
    Frequent hepatitis B virus rebound among HIV-hepatitis B virus-coinfected patients following antiretroviral therapy interruption.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    February 2010
43. RADZIO J , Yap SH, Tachedjian G, Sluis-Cremer N, et al
    N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
44. GATANAGA H , Ode H, Hachiya A, Hayashida T, et al
    Impact of human leukocyte antigen-B*51-restricted cytotoxic T-lymphocyte pressure on mutation patterns of nonnucleoside reverse transcriptase inhibitor resistance.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
45. CHARPENTIER C , Laureillard D, Piketty C, Tisserand P, et al
    High frequency of integrase Q148R minority variants in HIV-infected patients naive of integrase inhibitors.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
46. WAINBERG MA , Albert J
    Can the further clinical development of bevirimat be justified?
    AIDS. 2010.
    PubMed     Text format     Related articles   
    
    
    
    
47. KNOPS E , Kemper I, Schulter E, Pfister H, et al
    The evolution of protease mutation 76V is associated with protease mutation 46I and gag mutation 431V.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    January 2010
48. MASERATI R , De Silvestri A, Uglietti A, Colao G, et al
    Emerging mutations at virological failure of HAART combinations containing tenofovir and lamivudine or emtricitabine.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
49. GARDNER EM , Hullsiek KH, Telzak EE, Sharma S, et al
    Antiretroviral medication adherence and class- specific resistance in a large prospective clinical trial.
    AIDS. 2010;24:395-403.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
50. POVEDA E , Anta L, Blanco JL, Perez-Elias MJ, et al
    Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
51. HUDELSON SE , McConnell MS, Bagenda D, Piwowar-Manning E, et al
    Emergence and persistence of nevirapine resistance in breast milk after single-dose nevirapine administration.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
52. VINGERHOETS J , Tambuyzer L, Azijn H, Hoogstoel A, et al
    Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
    AIDS. 2010.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    December 2009
53. SLUIS-CREMER N , Moore K, Radzio J, Sonza S, et al
    N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
54. BEZEMER D , van Sighem A, Lukashov VV, van der Hoek L, et al
    Transmission networks of HIV-1 among men having sex with men in the Netherlands.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
55. ARRIBAS JR , Horban A, Gerstoft J, Fatkenheuer G, et al
    The MONET trial: darunavir/ritonavir with or without nucleoside analogues, for patients with HIV RNA below 50 copies/ml.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
56. MCMAHON MA , Siliciano JD, Kohli RM, Siliciano RF, et al
    Sensitivity of V75I HIV-1 reverse transcriptase mutant selected in vitro by acyclovir to anti-HIV drugs.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
57. MANOSUTHI W , Butler DM, Perez-Santiago J, Poon AF, et al
    Protease polymorphisms in HIV-1 subtype CRF01_AE represent selection by antiretroviral therapy and host immune pressure.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
58. LIDSTROM J , Li Q, Hoover DR, Kafulafula G, et al
    Addition of extended zidovudine to extended nevirapine prophylaxis reduces nevirapine resistance in infants who were HIV-infected in utero.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
59. SECLEN E , Gonzalez MD, Corral A, de Mendoza C, et al
    High prevalence of natural polymorphisms in Gag (CA-SP1) associated with reduced response to Bevirimat, an HIV-1 maturation inhibitor.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    November 2009
60. POZNIAK AL , Morales-Ramirez J, Katabira E, Steyn D, et al
    Efficacy and safety of TMC278 in antiretroviral-naive HIV-1 patients: week 96 results of a phase IIb randomized trial.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
61. PAREDES R , Cheng I, Kuritzkes DR, Tuomala RE, et al
    Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    October 2009
62. ASSOUMOU L , Cozzi-Lepri A, Brun-Vezinet F, Degruttola V, et al
    Development of a didanosine genotypic resistance interpretation system based on large derivation and validation datasets.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
63. SORIANO V , Perno CF, Kaiser R, Calvez V, et al
    When and how to use maraviroc in HIV-infected patients.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    
64. THURET I , Chaix ML, Tamalet C, Reliquet V, et al
    Raltegravir, etravirine and r-darunavir combination in adolescents with multidrug-resistant virus.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    September 2009
65. BUZON MJ , Dalmau J, Puertas MC, Puig J, et al
    The HIV-1 integrase genotype strongly predicts raltegravir susceptibility but not viral fitness of primary virus isolates.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    August 2009
66. KATLAMA C , Haubrich R, Lalezari J, Lazzarin A, et al
    Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    
    June 2009
67. FERNS RB , Kirk S, Bennett J, Williams I, et al
    The dynamics of appearance and disappearance of HIV-1 integrase mutations during and after withdrawal of raltegravir therapy.
    AIDS. 2009.
    PubMed     Text format     Related articles    Abstract available
    
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Flying Publisher website.    Design: